• 1
    Nguyen CT, Kattan MW. Development of a prostate cancer metagram: a solution to the dilemma of which prediction tool to use in patient counseling. Cancer 2009; 115 (Suppl.): 30393045
  • 2
    Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 21062131
  • 3
    Lughezzani G, Briganti A, Karakiewicz PI et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 2010; 58: 687700
  • 4
    Cooperberg MR, Freedland SJ, Pasta DJ et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006; 107: 23842391
  • 5
    Radiation Therapy Oncology Group. RTOG 0126 Protocol Information, 2/17/2011. Available at: Accessed January 2014
  • 6 PROFIT – Prostate Fractionated Irradiation Trial. 2006 January 11, 2013. Available at: Accessed January 2014
  • 7
    The R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2012
  • 8
    Al-Mamgani A, Heemsbergen WD, Levendag PC, Lebesque JV. Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiother Oncol 2010; 96: 1318
  • 9
    Kuban DA, Levy LB, Cheung MR et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011; 79: 13101317
  • 10
    Kupelian PA, Potters L, Khuntia D et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 2533
  • 11
    Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2013; 85: 686692
  • 12
    Castle KO, Hoffman KE, Levy LB et al. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys 2013; 85: 693699
  • 13
    Zumsteg ZS, Spratt DE, Pei X et al. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013; 85: 10121017
  • 14
    Radiation Therapy Oncology Group. RTOG 0815 Protocol Information, 2012. Available at: Accessed 14 May 2013
  • 15
    Rodrigues G, Yao X, Loblaw DA, Brundage M, Chin JL, Genitourinary Cancer Disease Site Group. Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer. Can Urol Assoc J 2013; 7: E411416
  • 16
    Khor R, Duchesne G, Tai KH et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys 2013; 85: 679685
  • 17
    Shen X, Keith SW, Mishra MV, Dicker AP, Showalter TN. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 2012; 83: 11541159
  • 18
    Frank SJ, Levy LB, van Vulpen M et al. Outcomes after prostate brachytherapy are even better than predicted. Cancer 2012; 118: 839847
  • 19
    Sita-Lumsden A, Dart DA, Waxman J, Bevan CL. Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer 2013; 108: 19251930
  • 20
    Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology 2008; 72: 396400
  • 21
    Halverson S, Schipper M, Blas K et al. The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse. Radiother Oncol 2011; 101: 513520
  • 22
    Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 5966
  • 23
    Denham JW, Steigler A, Wilcox C et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 2008; 9: 10581068
  • 24
    Vassil AD, Murphy ES, Reddy CA et al. Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology 2010; 76: 12511257
  • 25
    Zumsteg ZS, Zelefsky MJ. Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? Lancet Oncol 2012; 13: e259269